AVBP FY 2022 Earnings — ArriVent BioPharma, Inc. Common Stock Revenue & Financial Results | Market Cap Arena

AVBPArriVent BioPharma, Inc. Common Stock

$1B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$37M

Net Income

-$37M

EPS (Diluted)

$-1.10

Cash Flow

Operating Cash Flow

-$44M

Free Cash Flow

-$44M

Stock-Based Comp.

$424,000

Balance Sheet

Total Assets

$183M

Total Liabilities

$8M

Stockholders' Equity

$174M

Cash & Equivalents

$163M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$37M	-$9M	-324.4%
Net Income	-$37M	-$52M	+28.5%